Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 12:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 1,157 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Influenza vaccine Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain

NCT04978454
View directory record Official record
Conditions
Influenza
Interventions
Influenza RG-A/Texas/71/2017 (H3N2) Challenge, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 14, 2026, 12:45 PM EDT
Terminated Phase 2 Interventional Results available

Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)

NCT01924169
View directory record Official record
Conditions
Hematologic Disorder
Interventions
Lenalidomide, Influenza Vaccine, Pneumovax Vaccine
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Oct 14, 2026, 12:45 PM EDT
Completed Not applicable Interventional

Assessing Fever Rates in Children Ages 24 to 59 Months After Live Attenuated Influenza Vaccine (LAIV) or Inactivated Influenza Vaccines (IIV) Using Text Messaging for U.S. Influenza Vaccines in 2012-2013 & 2013-2014

NCT01764269
View directory record Official record
Conditions
Fever
Interventions
text message surveillance for fever
Other
Lead sponsor
Columbia University
Other
Eligibility
24 Months to 59 Months
Enrollment
656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Atlanta, Georgia • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2014 · Synced Oct 14, 2026, 12:45 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older

NCT07121192
View directory record Official record
Conditions
Influenza, Human
Interventions
Flu mRNA (Formulation A), Flu mRNA (Formulation B), Comparator 1, Comparator 2, Comparator 3
Biological · Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
776 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
22
States / cities
Anniston, Alabama • Fair Oaks, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 14, 2026, 12:45 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Sanofi H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations

NCT00943631
View directory record Official record
Conditions
Influenza
Interventions
Inactivated H1N1 Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
3
States / cities
Baltimore, Maryland • Durham, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Oct 14, 2026, 12:45 PM EDT
Completed Phase 3 Interventional Results available

Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza

NCT02287467
View directory record Official record
Conditions
Influenza A, Influenza B
Interventions
Intravenous hyperimmune immunoglobulin (IVIG), Placebo for IVIG
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
17
States / cities
San Diego, California • Denver, Colorado • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Oct 14, 2026, 12:45 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety of SAB-176 to Prevent the Flu, Given IM in Healthy Adults Compared With Placebo

NCT06435936
View directory record Official record
Conditions
PHA1A
Interventions
Single Ascending Dose of SAB-176, Single Ascending Dose of Placebo
Drug
Lead sponsor
SAb Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 14, 2026, 12:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Placebo-controlled,Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of MEDI8852 in Adults

NCT02350751
View directory record Official record
Conditions
Influenza
Interventions
MEDI8852, Placebo
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2015 · Synced Oct 14, 2026, 12:45 PM EDT
Completed Phase 2 Interventional Results available

Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications

NCT01227967
View directory record Official record
Conditions
Influenza
Interventions
Amantadine, Ribavirin, Oseltamivir, Oseltamivir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
881 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
69
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Oct 14, 2026, 12:45 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination

NCT02485639
View directory record Official record
Conditions
Influenza, Influenza Immunisation
Interventions
Influenza Virus Vaccine Inactivated
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Oct 14, 2026, 12:45 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults

NCT03658629
View directory record Official record
Conditions
Influenza, Human
Interventions
NanoFlu (Quad-NIV), Matrix-M Adjuvant, Placebo, Fluzone HD, Flublok Quadrivalent, Influenza Vaccine
Biological · Other
Lead sponsor
Novavax
Industry
Eligibility
65 Years and older
Enrollment
1,375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
14
States / cities
Hollywood, Florida • Savannah, Georgia • Stockbridge, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2022 · Synced Oct 14, 2026, 12:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Prophylactic Antipyretics on Immune Responses and Fever After 2014-2015 and 2015-2016 Inactivated Influenza Vaccine

NCT02212990
View directory record Official record
Conditions
Fever
Interventions
Acetaminophen Arm, Placebo Arm, Ibuprofen Arm
Other
Lead sponsor
Duke University
Other
Eligibility
6 Months to 47 Months
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Oct 14, 2026, 12:45 PM EDT
Completed Phase 2 Interventional Results available

Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine

NCT04025580
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Flucelvax, Fluvirin, Fluzone High Dose
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Oct 14, 2026, 12:45 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study of a Flu Vaccine in Children

NCT00001127
View directory record Official record
Conditions
Influenza
Interventions
Influenza virus vaccine (CAIV-T)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Months to 18 Years
Enrollment
15,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 14, 2026, 12:45 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Immune Responses to the Flu Shot During Pregnancy

NCT02148874
View directory record Official record
Conditions
Pregnancy
Interventions
influenza virus vaccination
Biological
Lead sponsor
Lisa Christian
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
287 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 14, 2026, 12:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Young Adult Influenza Vaccine Immunogenicity Substudy

NCT00170508
View directory record Official record
Conditions
Influenza
Interventions
Fluzone®
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 23, 2013 · Synced Oct 14, 2026, 12:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in Adults

NCT00382980
View directory record Official record
Conditions
Influenza
Interventions
Aluminum hydroxide, Inactivated Vero cell based whole virus influenza A/H5N1, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
308 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
5
States / cities
Stanford, California • Torrance, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2010 · Synced Oct 14, 2026, 12:45 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of the 2015-2016 Formulation of Fluzone® Quadrivalent (Influenza Vaccine) Among Healthy Children

NCT02539108
View directory record Official record
Conditions
Influenza
Interventions
Fluzone® Quadrivalent Influenza Vaccine, No Preservative
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 8 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Bardstown, Kentucky • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Oct 14, 2026, 12:45 PM EDT
Completed No phase listed Observational

Influenza in People With Normal and Weakened Immune Systems

NCT00533182
View directory record Official record
Conditions
Viral Infections, Respiratory Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 10, 2022 · Synced Oct 14, 2026, 12:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Live Influenza A Vaccine for Avian Influenza H7N7

NCT00922259
View directory record Official record
Conditions
Influenza A
Interventions
Influenza A H7N7 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2013 · Synced Oct 14, 2026, 12:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Early Immune Responses to Inactivated Influenza Vaccine: a Pilot Study

NCT01522248
View directory record Official record
Conditions
Influenza Virus Vaccine
Interventions
Trivalent Inactivated Influenza vaccine
Biological
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 14, 2026, 12:45 PM EDT
Completed Phase 1 Interventional

Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing In Gammopathy Patients

NCT02267733
View directory record Official record
Conditions
Influenza, Gammopathy
Interventions
Fluzone
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Oct 14, 2026, 12:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Protecting Pregnant Women From Infectious Diseases

NCT01761799
View directory record Official record
Conditions
Influenza, Pertussis
Interventions
P3 Vaccine Promotion Package.
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
11
States / cities
Athens, Georgia • Atlanta, Georgia • Bogart, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Oct 14, 2026, 12:45 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age

NCT04544267
View directory record Official record
Conditions
Influenza
Interventions
Quadrivalent influenza vaccine, high-dose, Quadrivalent influenza vaccine, standard dose
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 35 Months
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
10
States / cities
San Diego, California • Miami, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 14, 2026, 12:45 PM EDT